Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.

Clin Lung Cancer 2017 01 5;18(1):e35-e40. Epub 2016 Oct 5.

Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Introduction: We examined the effect of access to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy on survival for Asian female (AF) EGFR mutation-enriched patients with advanced lung adenocarcinoma.

Materials And Methods: We used the Surveillance Epidemiology and End Results database to study patients with stage IV lung adenocarcinoma diagnosed from 1998 to 2012. We compared survival (lung cancer-specific survival [LCSS] and overall survival) between AFs and non-Asian males (NAMs), an EGFR mutation-enriched and EGFR mutation-unenriched population, respectively, with a diagnosis in the pre-EGFR TKI (1998-2004) and EGFR TKI (2005-2012) eras. We used Cox proportional hazards models to examine the interaction of access to TKI treatment and EGFR enrichment status.

Results: Among 3029 AF and 35,352 NAM patients, we found that LCSS was best for AFs with a diagnosis in the TKI era (median, 14 months), followed by AFs with a diagnosis in the pre-TKI era (median, 8 months), NAMs with a diagnosis in the TKI era (median, 5 months), and NAMs with a diagnosis in the pre-TKI era (median, 4 months; log-rank P < .0001). In a multivariable model, the effect of a diagnosis in the TKI era on survival was greater for AFs than for NAMs (LCSS, P = .0020; overall survival, P = .0007). A lung cancer diagnosis in the TKI era was associated with an overall mortality decrease of 26% for AFs (hazard ratio, 0.740; 95% confidence interval, 0.682-0.80) and 15.9% for NAMs (hazard ratio, 0.841; 95% confidence interval, 0.822-0.860).

Conclusions: We found increased survival for lung adenocarcinoma diagnoses made after widespread access to EGFR TKIs, with the greatest increase among AF patients enriched for EGFR mutations. The present analysis eliminated the effect of crossover, which has complicated assessments of the survival advantage in EGFR TKI randomized trials.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.08.008DOI Listing
January 2017
15 Reads

Publication Analysis

Top Keywords

diagnosis tki
16
median months
16
era median
16
tki era
16
egfr
9
tki
9
survival
9
diagnosis pre-tki
8
months nams
8
egfr mutation-enriched
8
pre-tki era
8
95% confidence
8
confidence interval
8
afs diagnosis
8
kinase inhibitor
8
survival lung
8
hazard ratio
8
nams diagnosis
8
advanced lung
8
lung cancer
8

Similar Publications